Yoon Ah Park

Yoon Ah Park

Auto-generated profile, based on publicly available information

Yoon Ah Park

Department of General Surgery, Samsung Medical Center, Sungkyunkwan University, Seoul, Korea

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2014 in Diseases of the Colon & Rectum
Verified
Journal Article
Closed access
JYJung-A Yun
Jung-A Yun
KHKim Chang Hyun
Kim Chang Hyun
YPYoon Ah Park
Yoon Ah Park
YCYong Beom Cho
Yong Beom Cho
SYSeong Hyeon Yun
Seong Hyeon Yun
YCYong Beom Cho
Yong Beom Cho
The prognostic role of surgical resection of primary tumors is not well established in patients with asymptomatic unresectable stage IV colorectal cancer. The aims of this study were to reveal the prognostic role of surgical resection of primary tumors and to define prognostic factors affecting long-term oncological outcomes in patients with asymptomatic unresectable synchronous metastases. This study was a retrospective analysis of prospectively collected data. Between 2000 and 2008, a total of 416 patients with asymptomatic unresectable stage IV colorectal cancer were analyzed with propensity score matching. Prematching baseline characteristics were compared by bivariate analysis, and 113 pairs were selected after 1:1 matching with propensity scores estimated from logistic regression. The primary end point was overall survival. Among 416 patients, 218 (52.4%) underwent palliative resection of the primary tumor. Before propensity score matching, palliative resection resulted in a better survival rate than nonresection in univariate analysis (p < 0.001), but not in multivariate analysis (p = 0.08). After matching, the 5-year overall survival rate was significantly lower for patients with peritoneal metastasis and clinical M1b stage tumors in univariate analysis (p = 0.004 and p = 0.02). However, neither peritoneal metastasis nor clinical M1b stage showed any prognostic significance in multivariate analysis. The overall 5-year survival rate of the postmatching group was 4.9% and 3.5% in the palliative resection and nonresection groups. Consequently, palliative resection was not associated with a significant increase in survival compared with nonresection (p = 0.27). A subgroup analysis performed according to the site of metastasis also did not show any significant survival benefit of palliative resection after matching. Selection bias and potential confounders were limitations of this study. Resection of the primary tumor in patients with asymptomatic unresectable stage IV colorectal cancer was not associated with an improvement in overall survival after propensity score matching.

18 February 2016 in BMC Cancer
Verified
Journal Article
Open access
PDF file
HKHae Su Kim
Hae Su Kim
JHJin Seok Heo
Jin Seok Heo
JLJeeyun Lee
Jeeyun Lee
JLJi Yun Lee
Ji Yun Lee
MLMin-Young Lee
Min-Young Lee
YPYoung Suk Park
Young Suk Park
KRAS mutations are common in colorectal cancer (CRC). The role of KRAS mutation status as a prognostic factor remains controversial, and most large population-based cohorts usually consist of patients with non-metastatic CRC. We evaluated the impact of KRAS mutations on the time to recurrence (TTR) and overall survival (OS) in patients with metastatic CRC who underwent curative surgery with perioperative chemotherapy. Patients who underwent curative resection for primary and synchronous metastases were retrospectively collected in a single institution during a 6 year period between January 2008 and June 2014. Patients with positive surgical margins, those with known BRAF mutation, or those with an unknown KRAS mutation status were excluded, and a total of 82 cases were identified. The pathological and clinical features were evaluated. Patients’ outcome with KRAS mutation status for TTR and OS were investigated by univariate and multivariate analysis. KRAS mutations were identified in 37.8 % of the patients and not associated with TTR or OS between KRAS wild type and KRAS mutation cohorts (log-rank p = 0.425 for TTR; log-rank p = 0.137 for OS). When patients were further subdivided into three groups according to mutation subtype (wild-type vs. KRAS codon 12 mutation vs. KRAS codon 13 mutation) or amino acid missense mutation type (G > A vs. G > T vs. G > C), there were no significant differences in TTR or OS. Mutational frequencies were significantly higher in patients with lung metastases compared with those with liver and ovary/bladder metastases (p = 0.039), however, KRAS mutation status was not associated with an increased risk of relapsed in the lung. KRAS mutation was not associated with TTR or OS in patients with metastatic CRC who underwent curative surgery with perioperative chemotherapy.

13 March 2014 in Journal of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
KHKim Chang Hyun
Kim Chang Hyun
HKHee Cheol Kim
Hee Cheol Kim
SKSeok Hyung Kim
Seok Hyung Kim
YPYoon Ah Park
Yoon Ah Park
YCYong Beom Cho
Yong Beom Cho
YCYong Beom Cho
Yong Beom Cho

23 September 2025 in European Radiology
Verified
Journal Article
Closed access
PDF file
JYJeong Il Yu
Jeong Il Yu
YCYong Beom Cho
Yong Beom Cho
KGKyowon Gu
Kyowon Gu
JLJeong Hyun Lee
Jeong Hyun Lee
SBSun Young Baek
Sun Young Baek
KSKyoung Doo Song
Kyoung Doo Song

1 October 2017 in Archives of Physical Medicine and Rehabilitation
Verified
Journal Article
Closed access
PDF file
HLHannah Lee
Hannah Lee
ICIn Yae Cheong
In Yae Cheong
HKHyojeong Kang
Hyojeong Kang
ICIn Ho Chu
In Ho Chu
HKHee Cheol Kim
Hee Cheol Kim
JHJi Hye Hwang
Ji Hye Hwang